#### FINDING THE SWEET SPOT: DIABETES MELLITUS & HYPOGLYCEMIA IN MITOCHONDRIAL DISORDERS

Shana McCormack, MD, MTR Mitochondrial Medicine Frontier Program (thanks to Drs. Amy Goldstein & Marni Falk) April 14, 2023





### MITOCHONDRIAL DISORDERS IMPACT ENDOCRINE FUNCTION

- Multiple endocrine disorders have been associated with primary mitochondrial diseases.
- Certain sub-types have increased likelihood of endocrine disease.
- *Today's goal:* focus on blood sugar problems and related disorders.



#### Ng et al., NR Endo (PMID: 34644386)





- Diabetes mellitus & hypoglycemia
- Adrenal insufficiency
- Growth disorders
- *Not included here:* calcium homeostasis & bone health, thyroid disease, excess weight gain, hypogonadism (see resources)



### **PREVALENT & TREATABLE**

#### Endocrine Disorders in Primary Mitochondrial Disease

Iman S. Al-Gadi,<sup>1</sup> Richard H. Haus,<sup>2,3,3,5</sup> Marni J. Falk,<sup>5,3,7,8</sup> Amy Goldstein,<sup>5,6,7</sup> and Shana E. McCormaok<sup>5,7,0,9</sup>

- North American Mitochondrial Disease Consortium
- •N=404 (molecular diagnosis)
- *Common endocrine diagnoses:* atypical growth & sexual maturation (47%), diabetes mellitus (13%), hypothyroidism (6%)
- Other endocrine diagnoses: hypoglycemia, adrenal insufficiency, hypoparathyroidism, impaired bone health

Al-Gadi *et al., JES* 2018 (PMID: 29594260)



### **GLUCOSE HOMEOSTASIS**





#### **MITOCHONDRIAL DIABETES: SYMPTOMS**



Emergencies: diabetic ketoacidosis, hyperosmolar hyperglycemia



# SLMDMS, CASE #1 (FEMALE)

#### Height

#### BMI



Endocrinopathies: 4 yo: hypoparathyroidism; 8 yo: short stature; **10 yo: mitochondrial DM** Also has: ataxia, fine motor impairment, ptosis, SNHL, pancreatic insufficiency, pancreatitis, renal insufficiency, heart block



### MITOCHONDRIAL DIABETES: BEYOND "TYPE 1" & "TYPE 2"

- Diabetes: 37.3 million US individuals (CDC)
- Pre-diabetes: 96 million US adults (CDC)
- CDC: Type 1 (autoimmune, 5%), Type 2 (heterogeneous, weight-related, 90%), gestational, **"other"**
- Current framework does not work well!
- Abnormal glucose metabolism is common in mitochondrial disease.





# **MITOCHONDRIAL DIABETES: CASE**

- 6yo, excess urination and thirst
- Random blood sugar: 629 mg/dL (200 mg/dL+, consistent with DM)
- HbA1c 9.6% (reference, <5.7%)
- No ketones, no anti-pancreatic auto-antibodies
- Started insulin
- *Also:* ptosis, decreased tone, high lactate, retinal dystrophy, ECG with heart block
- Diagnosis: mtDNA deletion (KSS)



Amy Goldstein (CHOP MMFP); Chen et al., J Hum Genet 2011 (PMID: 21866113)



### MITOCHONDRIAL DIABETES: BEYOND "TYPE 1" & "TYPE 2"

- By some estimates, up to 5% of "typical" DM is mitochondrial (e.g., A3243G; A8296G; T14577C).
- DM is common in mtDNA deletions (e.g., KSS).
- DM occurs in nuclear mutations as well (e.g., *POLG*, *RRM2B*, *OPA1*).
- In children, DM has more acute onset, with **insulin deficiency** (e.g., DKA).
- In adults, DM has more insidious onset, more **insulin resistance**, still occurs at lower BMI, earlier age (~30's), and with more nephropathy/neuropathy (but less retinopathy) than "typical" T2D.



Karaa & Goldstein, *Pediatric Diabetes* 2015 (PMID: 25330715)



# **MITOCHONDRIAL DIABETES: TREATMENT**

#### ADA 2023 Guidelines for Intensification

### **Reasons for insulin:**

diabetic ketoacidosis, hyperglycemia causing dehydration or weight loss. Watch electrolytes!

**Consider novel agents** with appropriate risk/benefit balance and monitoring.

Avoid low's & ketones.

Use technology.





Yeung et al., J Diabetes Complications 2021 (PMID: 32331977)

### **MITOCHONDRIAL DIABETES: TECHNOLOGIES**

- Solutions exist for those with vision and mobility impairment.
- Novel forms of glucagon (e.g., premixed, intranasal) are valuable.
- Technologies exist to monitor blood sugar and deliver insulin (and transmit data).
- Automated insulin delivery systems are also available.



DM monitoring



# MITOCHONDRIAL DIABETES: SUMMARY

- *Insulin secretion* requires mitochondrial ATP production.
- Insulin resistance (e.g., in muscle) can occur.
- Educate regarding symptoms.
- Screen annually.
- **Manage** based on physiology, including blood ketones.
- Select medications based on **comorbidities** and risk for off-target effects.
- Use technology (CGM, pumps) where possible.



Yeung et al., J Diabetes Complications 2020 (PMID: 32331977)



- Symptoms: sweaty, shaky, pale, can proceed to seizure and unresponsiveness, **reversible** with carbohydrate.
- Look for **treatable causes** (e.g., malnutrition, cortisol deficiency, liver problems).
- Treat, reverse catabolism.
- Ideally, have an **emergency plan** and letter in place *before* illness.

#### Often (but not always):





- When evaluating, we divide into **ketotic** and **non-ketotic hypoglycemia**.
- Often, **"fasting"** hypoglycemia is **ketotic**.
- Often, **"reactive"** hypoglycemia is **non-ketotic**.
- Some individuals with metabolic disorders **cannot produce ketones**.



Adequate energy stores: burning mostly carbohydrate



**Limited energy stores:** burning mostly *fat* 





- Inpatient diagnostic fasting studies (controlled monitoring).
- Compare mitochondrial disease (suspected, confirmed) to idiopathic ketotic hypoglycemia.
- Fasting time was shorter, and ketone production was less.



Patrick Hanley, CHOP/Nemours



- *Initial evaluation:* check blood sugar when symptomatic, check after longest usual fasting interval.
- Goal blood sugar at least 70 mg/dL (less than 50 mg/dL = emergency).
- Check ketones (blood, not urine)!
- Ketones <0.6 mmol/L = trace.
- Next steps: based on findings.
- *Management:* surveillance, rescue, support.
- Watch out for NPO status!





# **ADRENAL INSUFFICIENCY**

- Mitochondria are critical for **steroid synthesis**.
- Symptoms of adrenal insufficiency: low blood sugar, low blood pressure, low sodium levels, especially with **critical illness**.



Williams, 12<sup>th</sup> edition





#### **ADRENAL INSUFFICIENCY: WHO NEEDS TESTING?**

- History of having received steroid medications (e.g., prednisone).
- Individuals with suggestive symptoms warrant testing.
- Empiric "stress steroids" are sometimes given in ICU settings.

**Table 1.** Descriptive statistics of clinical characteristics in pediatric intensive care unit (PICU) patients with and without mitochondrial disease.

Factor	Mitochondrial disease	Other diagnoses
Age in years, median (IOR)	7.6 (9.0)	4.6 (11. <del>6</del> )
Length of stay in days, median (IOR)	2.9 (5.6)	1.Z (2.9)
Mortality, 1% deceased	15.0 <sup>24</sup> 96	2.4%
PRISM score median (IQR)	3 (6)	2 (5)
PIM2 score (KOR)	-3.38 (1.88)	-4,74 (2,02)
Hours on ventilator, median (IOR)	Z1.5 (18Z.Z)	14.0 (49.5)

Ehinger et al., Ped Res 2021 (PMID: 33627817)

**Children's Hospital** 

20

# SLMDMS, CASE #1 (FEMALE)

#### Height

#### BMI



Endocrinopathies: 4 yo: hypoparathyroidism; **8 yo: short stature**; 10 yo: mitochondrial DM Also has: ataxia, fine motor impairment, ptosis, SNHL, pancreatic insufficiency, pancreatitis, renal insufficiency, heart block



# **GROWTH REQUIRES ENERGY**

- Impaired growth can be the presentation of mitochondrial disease.
- *Example case:* 11yo, post-natal growth failure (also had fatigue, hypothyroidism, and eye findings).



#### Height &



Holloman et al., BMJ Case Rep 2013 (PMID: 23420719)



### **GROWTH TRAJECTORIES**

BMDCS, F Mito, F BMDCS, M – Mito, M 180 160 160 Height (cm) Height (cm) Girls (n=62, mean): Boys (n=74, mean): Height Z-score -0.84 Height Z-score -0.70 120 120 BMI Z-score 0.15 BMI Z-score 0.14 APV: 11.6y (vs. 11.6) APV: 13.4y (vs. 13.4y) PHV: 7.8 cm/yr (vs. 7.9) PHV: 9.0 cm/yr (vs. 10.0) 20 20 10 15 10 15 Age (years) Age (years) **CHOP MMFP** 

> Children's Hospital of Philadelphia<sup>®</sup>

Short stature becomes more pronounced at puberty.

# **CAUSES OF IMPAIRED GROWTH**

- Nutrition/GI disorders
- Other endocrine disorders, including hypothyroidism or sex steroid deficiency
- Growth hormone deficiency
- Stress/adaptation?



Classes of mitochondrial disorders (CHOP MMFP):
1) Complex assembly; 2) Membrane Function; 3) mtDNA deletion;
4) mtDNA maintenance; 5) Translation

**BMI** 



Height

# **GROWTH HORMONE: DECISION TO TREAT?**

- **Symptoms:** short stature or decreased growth velocity, low blood sugar, fatigue, decreased muscle mass, impaired bone density
- •Assessment: exclude/mitigate other causes, IGF1/IFBP3, consider GDF15, provocative testing
- Management: consider GH (adult vs. pediatric dosing)
- Other considerations: adverse effects of GH (stress, DM), patient-specific risk/benefit balance, manage expectations





- Endocrine disorders are prevalent in individuals with mitochondrial disorders.
- Evidence-supported and symptom-directed patient screening is appropriate.
- Identify opportunities for effective interventions.







#### **MANY THANKS!**

